$
6.35
11:08 PM EST
Business Description
Cipher Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA17253X1050
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 112.96 | |||||
Equity-to-Asset | 0.94 | |||||
Debt-to-EBITDA | 0.03 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 19.67 | |||||
Beneish M-Score | -2.43 | |||||
WACC vs ROIC |
Growth Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.4 | |||||
3-Year EBITDA Growth Rate | 16.4 | |||||
3-Year EPS without NRI Growth Rate | 41.2 | |||||
3-Year FCF Growth Rate | 17.8 | |||||
3-Year Book Growth Rate | 42.7 | |||||
Future 3-5Y Total Revenue Growth Rate | 1.47 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 41.57 | |||||
9-Day RSI | 48.97 | |||||
14-Day RSI | 52.57 | |||||
6-1 Month Momentum % | 98.46 | |||||
12-1 Month Momentum % | 146.31 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.19 | |||||
Quick Ratio | 8.62 | |||||
Cash Ratio | 7.58 | |||||
Days Inventory | 231.72 | |||||
Days Sales Outstanding | 103.34 | |||||
Days Payable | 439.93 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 3.8 | |||||
Shareholder Yield % | 3.57 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 80.77 | |||||
Operating Margin % | 47.42 | |||||
Net Margin % | 96.26 | |||||
FCF Margin % | 75.6 | |||||
ROE % | 28.3 | |||||
ROA % | 24.94 | |||||
ROIC % | 42.81 | |||||
ROC (Joel Greenblatt) % | 905.42 | |||||
ROCE % | 13.89 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 8.04 | |||||
Forward PE Ratio | 14.93 | |||||
PE Ratio without NRI | 8.31 | |||||
Shiller PE Ratio | 39.71 | |||||
Price-to-Owner-Earnings | 12.41 | |||||
PEG Ratio | 0.4 | |||||
PS Ratio | 7.8 | |||||
PB Ratio | 1.94 | |||||
Price-to-Tangible-Book | 2.47 | |||||
Price-to-Free-Cash-Flow | 10.33 | |||||
Price-to-Operating-Cash-Flow | 10.33 | |||||
EV-to-EBIT | 11.4 | |||||
EV-to-EBITDA | 10.16 | |||||
EV-to-Revenue | 5.4 | |||||
EV-to-Forward-Revenue | 5.61 | |||||
EV-to-FCF | 7.31 | |||||
Price-to-Projected-FCF | 0.95 | |||||
Price-to-Median-PS-Value | 2.79 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.47 | |||||
Price-to-Graham-Number | 0.97 | |||||
Price-to-Net-Current-Asset-Value | 3.65 | |||||
Price-to-Net-Cash | 4.54 | |||||
Earnings Yield (Greenblatt) % | 8.77 | |||||
FCF Yield % | 10.49 | |||||
Forward Rate of Return (Yacktman) % | 24.48 |